Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Save the Date for the International Immunology Summit 2021: #TheSatelliteMeeting 27th October #ImmunologySummit2021 https://t.co/W9mq7FmHdc
— UCB News (@ucb_news) 17.09.2021 -
Innovative antibody engineering research opens the way for a potential new class of cancer treatments. Read more about the @CommsBio publication here: https://t.co/raU7BcdQGz
— UCB News (@ucb_news) 14.09.2021 -
Over the past year, we've been inspired by the #AdvantageHers community and the outpouring of support for our campaign partner @CaroWozniacki’s rheumatoid arthritis story. Here’s to another great year - click for more: https://t.co/33gbJ56QXW
— UCB News (@ucb_news) 13.09.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
